Intuitive Surgical, Inc. $ISRG Shares Sold by E. Ohman J or Asset Management AB

Key Points

• E. Ohman J or Asset Management AB reduced its stake in Intuitive Surgical by 5.8%, now owning 27,183 shares valued at approximately $14.77 million.
• Analysts remain positive on Intuitive Surgical, with 13 analysts rating it as a Buy and an average price target of $595.95, reflecting a recent increase from previous forecasts.
• Intuitive Surgical reported a strong quarterly performance with $2.19 EPS, exceeding expectations, and a revenue increase of 21.4% year-over-year.

E. Ohman J or Asset Management AB lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,183 shares of the medical equipment provider's stock after selling 1,676 shares during the period. E. Ohman J or Asset Management AB's holdings in Intuitive Surgical were worth $14,772,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Chilton Capital Management LLC grew its position in Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 43 shares during the period. Global Financial Private Client LLC grew its position in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares during the period. Elite Financial Inc. acquired a new stake in shares of Intuitive Surgical during the 1st quarter valued at about $26,000. LFA Lugano Financial Advisors SA purchased a new position in shares of Intuitive Surgical in the 1st quarter valued at about $30,000. Finally, TD Capital Management LLC raised its holdings in Intuitive Surgical by 300.0% in the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 45 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Piper Sandler restated an "overweight" rating and issued a $595.00 price objective (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Citigroup reissued a "buy" rating and issued a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Wells Fargo & Company increased their price objective on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a report on Wednesday, July 23rd. Truist Financial lifted their target price on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Finally, BTIG Research raised their price target on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Thirteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $449.68 on Monday. The stock's 50 day simple moving average is $485.67 and its 200-day simple moving average is $507.82. The stock has a market cap of $161.20 billion, a P/E ratio of 62.72, a P/E/G ratio of 4.71 and a beta of 1.61. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. The firm had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The firm's revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.78 earnings per share. As a group, research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Activity

In other news, Director Amy L. Ladd sold 336 shares of the business's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $470.11, for a total transaction of $157,956.96. Following the transaction, the director owned 1,074 shares of the company's stock, valued at approximately $504,898.14. The trade was a 23.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president owned 353 shares of the company's stock, valued at approximately $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,224 shares of company stock valued at $21,716,492. 0.70% of the stock is currently owned by insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.